Single visit rabies pre-exposure prophylaxis: A literature review

Background: The current WHO-recommended rabies pre-exposure prophylaxis (PrEP) are two-visit vaccination schedules, but there are studies suggesting that single visit schedules might be sufficient to prime the immunity.Methods: A literature review was conducted to retrieve and summarize published data on single visit rabies PrEP. PubMed database was screened for articles published between January 1st, 2003 and December 31st, 2022. The bibliographies of the articles chosen to undergo full text review and of the current major WHO publications on rabies were searched to find additional references, regardless of publication date. The primary outcome was the percentage of subjects having received rabies PrEP on single visit schedules who achieved antibody levels & GE;0.5 IU/mL one week after post-exposure prophylaxis (PEP), regardless of the PEP regimen. Results: 11 studies were selected for inclusion, totalling 935 subjects, of which 696 received a simulated PEP schedule. Of these 696, a serological test result on day 7 was available for 408 of them, and 406 subjects (99.51%) seroconverted after PEP without any difference regarding time delay between PrEP and PEP or the vaccination schedule used for PEP.Conclusion: Single visit PrEP schedules seem to confer sufficient protection in most healthy individuals without immunocompromised status if a booster PEP is administered after a suspected rabies exposure. Further studies in real-life settings and in different age categories are needed to confirm this finding, which may increase the availability of vaccines and thus the accessibility of PrEP for vulnerable populations.

Automated summary

A literature review found that single visit rabies pre-exposure prophylaxis (PrEP) might be sufficient to prime the immunity. Results from 11 studies showed that 99.51% of subjects achieved sufficient protection one week after vaccination, regardless of the vaccination schedule. Therefore, single visit PrEP seems to provide adequate protection in most healthy individuals, potentially increasing the accessibility and usability of vaccines.